{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:14:46Z","timestamp":1779279286518,"version":"3.51.4"},"reference-count":11,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypothalamic obesity (HO) is a severe complication of suprasellar tumors characterized by hyperphagia, rapid weight gain, and resistance to lifestyle interventions. We describe a case of a woman diagnosed with suprasellar germinoma at 16 years of age who was treated with chemotherapy and radiotherapy. Subsequently, she experienced progressive weight gain, increasing from 57\u2005kg to a peak of 138\u2005kg by age 37 years, and developed type 2 diabetes mellitus at age 28 years. At age 38 years, she presented with polydipsia, polyuria, and fatigue, and was admitted for the management of hyperglycemia with class III obesity (123.5\u2005kg; body mass index [BMI], 51.4\u2005kg\/m2). Intensive insulin therapy (up to 100 units\/day) resolved glucotoxicity. After initiation of semaglutide (titrated from 0.25 to 0.5\u2005mg\/week), appetite markedly decreased, and subsequent weight loss was achieved. Three months after discharge, her weight decreased from 131\u2005kg to 112.1\u2005kg, representing an approximate 14% reduction, accompanied by optimized glycemic control. Body composition analysis revealed that weight loss was primarily due to fat mass reduction with relative preservation of muscle mass. This case demonstrates the potential efficacy of semaglutide in patients with HO and type 2 diabetes mellitus after suprasellar germinoma treatment.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag107","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:43:50Z","timestamp":1774529030000},"source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-182X","authenticated-orcid":false,"given":"Kenichi","family":"Yokota","sequence":"first","affiliation":[{"name":"Division of Metabolism and Endocrinology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanami","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Kusuda","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Sone","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"3","key":"2026052007564544600_luag107-B1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/jdi.14372","article-title":"Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity","volume":"16","author":"Ma","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"3","key":"2026052007564544600_luag107-B2","doi-asserted-by":"crossref","first-page":"e12642","DOI":"10.1111\/cob.12642","article-title":"The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review","volume":"14","author":"Ng","year":"2024","journal-title":"Clin Obes"},{"key":"2026052007564544600_luag107-B3","doi-asserted-by":"crossref","first-page":"1256514","DOI":"10.3389\/fendo.2023.1256514","article-title":"Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon","volume":"14","author":"Roth","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026052007564544600_luag107-B4","doi-asserted-by":"crossref","first-page":"bvae200","DOI":"10.1210\/jendso\/bvae200","article-title":"Treatment of hypothalamic obesity with GLP-1 analogs","volume":"9","author":"Dimitri","year":"2024","journal-title":"J Endocr Soc"},{"issue":"4","key":"2026052007564544600_luag107-B5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000509302","article-title":"Experiences with glucagon-like peptide-1 receptor agonist in children with acquired hypothalamic obesity","volume":"13","author":"van Schaik","year":"2020","journal-title":"Obes Facts"},{"issue":"2","key":"2026052007564544600_luag107-B6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity","volume":"23","author":"Roth","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2026052007564544600_luag107-B7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11102-024-01429-5","article-title":"Semaglutide treatment of hypothalamic obesity - a real-life data study","volume":"27","author":"Svendstrup","year":"2024","journal-title":"Pituitary"},{"issue":"5","key":"2026052007564544600_luag107-B8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s11102-024-01426-8","article-title":"Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma","volume":"27","author":"Gjersdal","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"2026052007564544600_luag107-B9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/dom.70216","article-title":"Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: a multicentre real-world study","volume":"28","author":"Lambert","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2026052007564544600_luag107-B10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-025-01564-7","article-title":"Semaglutide treatment in hypothalamic obesity: two-year outcomes on body composition, appetite, and quality of life","volume":"28","author":"Gjersdal","year":"2025","journal-title":"Pituitary"},{"issue":"3","key":"2026052007564544600_luag107-B11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cen.15262","article-title":"The efficacy of semaglutide on hypothalamic obesity caused by craniopharyngioma surgery","volume":"103","author":"Wang","year":"2025","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/6\/luag107\/68316670\/luag107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/6\/luag107\/68316670\/luag107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:57:02Z","timestamp":1779278222000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag107\/8684014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,4,29]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag107","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,29]]},"article-number":"luag107"}}